← Back to Search

Glucagon Response Study for Non-alcoholic Fatty Liver Disease

Phase 1 & 2
Recruiting
Research Sponsored by Adrian Vella
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 240 minutes of study
Awards & highlights

Study Summary

This trial is examining whether or not glucagon resistance is caused by obesity, hepatic steatosis, or a combination of the two in people with and without type 2 diabetes.

Who is the study for?
This trial is for adults with obesity, Type 2 Diabetes, or Non-alcoholic Fatty Liver Disease who can consent to participate. It's not suitable for those with a history of certain abdominal surgeries, MRI contraindications like metal implants or claustrophobia, severe anemia (low hematocrit), abnormal thyroid levels (TSH), active illness/malignancy, significant vascular disease symptoms, or high alcohol consumption.Check my eligibility
What is being tested?
The study investigates how glucagon—a hormone that affects blood sugar—interacts with liver metabolism in people who are lean and obese and may have Type 2 Diabetes. The focus is on understanding glucagon's role in breaking down amino acids and its relationship with liver fat content.See study design
What are the potential side effects?
While the specific side effects aren't listed here, studies involving hormones like glucagon could potentially affect blood sugar levels and cause reactions at the injection site if applicable.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~240 minutes of study
This trial's timeline: 3 weeks for screening, Varies for treatment, and 240 minutes of study for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Rate of Amino acid catabolism in the presence / absence of glucagon
Secondary outcome measures
Effect of Diabetes on amino-acid catabolism

Trial Design

3Treatment groups
Experimental Treatment
Group I: Obese AdultsExperimental Treatment1 Intervention
We will study 20 subjects on one occasion using a hyperglycemic clamp with 2 doses of glucagon.
Group II: Healthy AdultsExperimental Treatment1 Intervention
We will study 20 subjects on one occasion using a hyperglycemic clamp with 2 doses of glucagon.
Group III: Adults with Type 2 DiabetesExperimental Treatment1 Intervention
We will study 20 subjects on one occasion using a hyperglycemic clamp with 2 doses of glucagon.

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Adrian VellaLead Sponsor
8 Previous Clinical Trials
149 Total Patients Enrolled

Media Library

Glucagon response study Clinical Trial Eligibility Overview. Trial Name: NCT05500586 — Phase 1 & 2
Type 2 Diabetes Research Study Groups: Adults with Type 2 Diabetes, Healthy Adults, Obese Adults
Type 2 Diabetes Clinical Trial 2023: Glucagon response study Highlights & Side Effects. Trial Name: NCT05500586 — Phase 1 & 2
Glucagon response study 2023 Treatment Timeline for Medical Study. Trial Name: NCT05500586 — Phase 1 & 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many individuals are being asked to participate in this clinical research?

"Yes, that is correct. The clinicaltrial.gov website has information revealing that this study is actively looking for patients. This trial was first posted on 10/20/2022 and the most recent update was 11/1/2022. 1 location is admitting 60 participants into the study."

Answered by AI

Are geriatric patients being accepted into this clinical research?

"The age requirement for this clinical trial is that patients must be over 25 but younger than 65."

Answered by AI

Could I take part in this clinical trial if I qualified?

"To be eligible for this research, individuals must suffer from obesity and fall between the ages of 25-65. Currently, the trial has room for 60 more patients."

Answered by AI

Are we still enrolling participants for this experiment?

"That is correct. The listing on clinicaltrials.gov notes that the study is open for enrollment and has been since October 20th, 2022. Sixty people are needed to take part in the research being conducted at a single site."

Answered by AI

Who else is applying?

What state do they live in?
Minnesota
What site did they apply to?
Mayo Clinic in Rochester
What portion of applicants met pre-screening criteria?
Did not meet criteria
Met criteria
How many prior treatments have patients received?
1

Why did patients apply to this trial?

I want to get relived from diabetes 2 and it’s complications like fatty liver.
PatientReceived 1 prior treatment
Recent research and studies
clinicaltrials.govStudy
The Effects of Glucagon on Hepatic Metabolism
Adrian Vella 2022. "The Effects of Glucagon on Hepatic Metabolism". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05500586.
All > Fatty Liver Disease
~11 spots leftby Sep 2024
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top